Pipeline
Alevin’s preclinical pipeline features small molecules that target integrin receptors. Our broad intellectual property estate contains an array of inhibitors that show both potency and isoform-selectivity in cell adhesion assays.
Examples from core platform and pipeline for partner programs
ALV296
Target: αvβ6
Properties:
- IC50 nanomolar; 10-100-fold selectivity over other αv integrins
- Rapid metabolic clearance
- 14-day repeat dosing study in rats at 30 mg/kg with no adverse effects; no off target effects
Potential application: undisclosed
ALV021
Target: αvβ6
Properties:
IC₅₀ nanomolar; 100-fold selectivity vs. αvβ1
DMPK – rapid metabolic clearance
Potential application: undisclosed
ALV2007
Target: pan αv
Properties:
IC₅₀ nanomolar across 5 integrins
DMPK – 100% oral bioavailability in mouse
Potential application: oral treatment for kidney fibrosis
ALV3008
Target: αvβ1/αvβ8
Properties:
IC₅₀ nanomolar vs. αvβ1/αvβ8
Potential application: oncology
ALV073
Target: αvβ6
Properties:
IC₅₀ nanomolar vs. αvβ6; contains linker chain for targeted delivery of “warhead”
Potential application: targeted radiotherapy